These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9321760)

  • 1. Cost effectiveness of DNA diagnosis for four monogenic diseases.
    van der Riet AA; van Hout BA; Rutten FF
    J Med Genet; 1997 Sep; 34(9):741-5. PubMed ID: 9321760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of antenatal screening for cystic fibrosis.
    Cuckle HS; Richardson GA; Sheldon TA; Quirke P
    BMJ; 1995 Dec; 311(7018):1460-3; discussion 1463-4. PubMed ID: 8520332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs, effects, and savings of screening for cystic fibrosis gene carriers.
    Wildhagen MF; Hilderink HB; Verzijl JG; Verheij JB; Kooij L; Tijmstra T; ten Kate LP; Habbema JD
    J Epidemiol Community Health; 1998 Jul; 52(7):459-67. PubMed ID: 9799881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The resource implications and service outcomes of genetic services in the context of DNA technology.
    Beech R; Rona RJ; Mandalia S
    Health Policy; 1994 Jan; 26(3):171-90. PubMed ID: 10133130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
    Lieu TA; Watson SE; Washington AE
    Obstet Gynecol; 1994 Dec; 84(6):903-12. PubMed ID: 7970468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA analysis and genetic counselling in Duchenne muscular dystrophy.
    Gardner RJ; Wilson SJ; Wilkins RJ
    N Z Med J; 1988 Jul; 101(849):455-7. PubMed ID: 3399183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carrier detection and prenatal diagnosis of Duchenne/Becker muscular dystrophy (D/BMD) by DNA-analysis.
    Bakker E; Bonten EJ; den Dunnen JT; Veenema H; Grootscholten PM; van Ommen GJ; Pearson PL
    Prog Clin Biol Res; 1989; 306():51-67. PubMed ID: 2662213
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost effectiveness of antenatal screening for cystic fibrosis. Couple screening should be preferred for medical reasons.
    Morris J
    BMJ; 1996 Apr; 312(7035):908-9; author reply 910. PubMed ID: 8611894
    [No Abstract]   [Full Text] [Related]  

  • 9. Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing.
    Wilson RD; De Bie I; Armour CM; Brown RN; Campagnolo C; Carroll JC; Okun N; Nelson T; Zwingerman R; Audibert F; Brock JA; Brown RN; Campagnolo C; Carroll JC; De Bie I; Johnson JA; Okun N; Pastruck M; Vallée-Pouliot K; Wilson RD; Zwingerman R; Armour C; Chitayat D; De Bie I; Fernandez S; Kim R; Lavoie J; Leonard N; Nelson T; Taylor S; Van Allen M; Van Karnebeek C
    J Obstet Gynaecol Can; 2016 Aug; 38(8):742-762.e3. PubMed ID: 27638987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variables that underlie cost efficacy of prenatal screening.
    Kinzler WL; Morrell K; Vintzileos AM
    Obstet Gynecol Clin North Am; 2002 Jun; 29(2):277-86, v-vi. PubMed ID: 12108828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of antenatal screening for cystic fibrosis. Realistic cost must be established for genetic counselling in two step screening.
    Brock DJ
    BMJ; 1996 Apr; 312(7035):908; author reply 910. PubMed ID: 8611893
    [No Abstract]   [Full Text] [Related]  

  • 12. Duchenne muscular dystrophy, cystic fibrosis, myotonic dystrophy: gene to protein.
    Robinson A
    CMAJ; 1993 Jun; 148(11):1975-9. PubMed ID: 8500034
    [No Abstract]   [Full Text] [Related]  

  • 13. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis.
    Massie J; Forbes R; Dusart D; Bankier A; Delatycki MB
    J Paediatr Child Health; 2007 Nov; 43(11):721-3. PubMed ID: 17924936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carrier screening for cystic fibrosis: costs and clinical outcomes.
    Asch DA; Hershey JC; Dekay ML; Pauly MV; Patton JP; Jedrziewski MK; Frei F; Giardine R; Kant JA; Mennuti MT
    Med Decis Making; 1998; 18(2):202-12. PubMed ID: 9566453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of prenatal population screening for fragile X syndrome.
    Hollingsworth B; Harris A
    Community Genet; 2005; 8(2):68-72. PubMed ID: 15925881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic counseling of isolated carriers of Duchenne muscular dystrophy.
    Hoffman EP; Pegoraro E; Scacheri P; Burns RG; Taber JW; Weiss L; Spiro A; Blattner P
    Am J Med Genet; 1996 Jun; 63(4):573-80. PubMed ID: 8826437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetics in clinical practice: evolution of a DNA diagnostic service.
    Meredith AL; Upadhyaya M; Harper PS
    BMJ; 1988 Oct; 297(6652):843-6. PubMed ID: 2972330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic counseling and prenatal diagnosis in Duchenne myopathy: yesterday, today and tomorrow].
    Kaplan J; Briard ML; Jeanpierre M; Kaplan JC; Frézal J
    J Genet Hum; 1987 Jan; 35(1):3-18. PubMed ID: 2881972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and molecular genetic approach to Duchenne and Becker muscular dystrophy: an updated protocol.
    van Essen AJ; Kneppers AL; van der Hout AH; Scheffer H; Ginjaar IB; ten Kate LP; van Ommen GJ; Buys CH; Bakker E
    J Med Genet; 1997 Oct; 34(10):805-12. PubMed ID: 9350811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scientific basis for cost-benefit analysis of genetics services.
    Modell B; Kuliev AM
    Trends Genet; 1993 Feb; 9(2):46-52. PubMed ID: 8456501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.